Comparison between different techniques for treatment of submacular haemorrhage due to Age-Related Macular Degeneration

Eur J Ophthalmol. 2021 Sep;31(5):2621-2624. doi: 10.1177/1120672120959551. Epub 2020 Sep 29.

Abstract

Purpose: To compare the outcome of vitrectomy, subretinal tissue plasminogen activator (TPA), and gas with and without subretinal air versus Intravitreal TPA and gas in the treatment of submacular haemorrhage (SMH) due to Neovascular age related macular degeneration.

Methods: We analysed the notes of 29 cases presented with SMH in the period between 01/2016 and 09/2018 at James Cook University Hospital. Presenting visual acuity (BCVA), size and location of SMH, Procedure done, final BCVA at 6 months and any surgical complications were recorded. 11 Cases (Group 1) received intravitreal TPA (50 µg in 0.1 ML), 0.3 ml of pure sulfur hexafluoride (SF6). 18 cases (Group 2) received 23 G Pars Plana vitrectomy, Subretinal TPA injection (25 µg in 0.1 ml), and 20% SF6 gas filling. Group 2 was further divided into 2A (10 patients) who received only subretinal TPA and group 2B (8 patients) who received additional 0.1 ml subretinal air.

Results: The mean BCVA at presentation was 0.0068 in group 1 and 0.0067 in group 2 (p = 0.8734). The mean postoperative BCVA at 6 months was 0.31 in group 1 and 0.58 in group 2 (p = 0.0015). Subgroup analysis of group 2 didn't show statistically significant difference in outcome when adding subretinal air to the vitrectomy procedure (p = 0.7009).

Conclusion: Vitrectomy, gas and subretinal TPA has more successful displacement rate and better visual outcome than Intravitreal TPA & Gas alone in treating SMH involving the fovea in age-related macular degeneration. Additional subretinal air doesn't seem to improve the outcome in cases having vitrectomy.

Keywords: Macular degeneration; submacular haemorrhage; subretinal injection; tissue plasminogen activator; vitrectomy.

MeSH terms

  • Endotamponade
  • Fibrinolytic Agents / therapeutic use
  • Fluorescein Angiography
  • Humans
  • Macular Degeneration* / complications
  • Macular Degeneration* / drug therapy
  • Retinal Hemorrhage / drug therapy
  • Retinal Hemorrhage / therapy
  • Retrospective Studies
  • Tissue Plasminogen Activator*
  • Treatment Outcome
  • Vitrectomy

Substances

  • Fibrinolytic Agents
  • Tissue Plasminogen Activator